Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation

24 Nov 2015

Abstract excerpt

OBJECTIVE: Resistance to emtricitabine plus tenofovir disoproxil fumarate (FTC/TDF) or TDF alone used as preexposure prophylaxis (PrEP) has been detected in individuals who initiated PrEP during unrecognized acute HIV infection and, rarely, in PrEP breakthrough infections. PrEP-selected resistance could alter future treatment options, and therefore we sought to determine how long resistance persisted after PrEP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26731753
DOI: 10.1097/qad.0000000000000915

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessationPMID 26731753Read ↗

HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.Semantic proximity Read ↗

Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial.Semantic proximity Read ↗

Pre-exposure Prophylaxis Use History in People With Antiretroviral Resistance at HIV Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015-2022.Semantic proximity Read ↗

Low clinical impact of HIV drug resistance mutations in oral pre-exposure prophylaxis: a systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacokinetics, pharmacodynamics, efficacy and drug resistance selection of injectable long-acting lenacapavir pre-exposure prophylaxis (PrEP) against HIVSemantic proximity Read ↗

Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention.Semantic proximity Read ↗

HIV, transmitted drug resistance, and the paradox of preexposure prophylaxisSemantic proximity Read ↗

Reversal periods and patterns from drug-resistant to wild-type HIV type 1 after cessation of anti-HIV therapy.Semantic proximity Read ↗

Oral Pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populationsSemantic proximity Read ↗

A Darwinian model for the evolution of drug resistance to long-acting PrEP during an early HIV infection.Semantic proximity Read ↗

Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis.Semantic proximity Read ↗

Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.